Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 6Phase 1 3Phase 4 2Phase 3 1Phase 2/3 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Specimen Handling 5Enoxaparin 5Carboplatin 5Bevacizumab 5Nivolumab 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × enfortumab vedotin × Clear all
NCT06862219 2026-05-28

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Astellas Pharma Inc

Phase 4 Recruiting
100 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡